Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
OSE-279 by OSE Immunotherapeutics for Hepatocellular Carcinoma: Likelihood of Approval
OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
OSE-279 by OSE Immunotherapeutics for Sarcomas: Likelihood of Approval
OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
OSE-279 by OSE Immunotherapeutics for Anal Cancer: Likelihood of Approval
OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
OSE-279 by OSE Immunotherapeutics for Thyroid Cancer: Likelihood of Approval
OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase...